The present disclosure relates to a novel thiol reductant having the formula (I), the preparation and the use in the preparation of an antibody with thiol group site-specific modifications with improved homogeneity.

The present disclosure relates to a novel thiol reductant having the formula (I), the preparation and the use in the preparation of an antibody with thiol group site-specific modifications with improved homogeneity.

The present disclosure relates to compounds that are capable of inhibiting creatine kinase. The present disclosure also relates to methods of treating cancer, such as hematological malignancies.

The present disclosure provides compounds of Formula I, a free base form thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising the same, and methods of treating medical disorders using the same.